PTC Therapeutics (NASDAQ:PTCT) plays a key role in rare disease treatments, contributing to the Nasdaq Index healthcare ...
Jennifer DiRico Appointed as Next Chief Financial Officer ...
PTC Therapeutics (NASDAQ:PTCT) saw California-based Palo Alto Investors increase its position by 456,144 shares in the third ...
PTC’s strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its ...
PTC Inc. PTC is scheduled to report third-quarter fiscal 2025 results on July 30, after market close. For the quarter, PTC anticipates revenues between $560 million and $600 million. Non-GAAP EPS is ...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze ...
Fintel on MSN
RBC Capital Downgrades PTC Therapeutics (PTCT)
Fintel reports that on December 1, 2025, RBC Capital downgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Outperform to Sector Perform. Analyst Price Forecast Suggests 1.62% Upside As of ...
“We”—old timers, old heads, just plain old—sometimes refer to ourselves as “fossils,” but we’re not really. Fossils, as far as “we” know, can’t think, change positions, make jokes, whine, or delude ...
PTC Inc. PTC is scheduled to report first-quarter fiscal 2022 results on Jan 26, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 66.7%, surpassing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback